Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement prod… Read more
Edwards Lifesciences Corp (EW) - Total Assets
Latest total assets as of September 2025: $13.27 Billion USD
Based on the latest financial reports, Edwards Lifesciences Corp (EW) holds total assets worth $13.27 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Edwards Lifesciences Corp - Total Assets Trend (1999–2024)
This chart illustrates how Edwards Lifesciences Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Edwards Lifesciences Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Edwards Lifesciences Corp's total assets of $13.27 Billion consist of 48.1% current assets and 51.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $3.05 Billion | 23.3% |
| Accounts Receivable | $727.40 Million | 5.6% |
| Inventory | $1.09 Billion | 8.3% |
| Property, Plant & Equipment | $1.78 Billion | 13.7% |
| Intangible Assets | $1.18 Billion | 9.0% |
| Goodwill | $1.78 Billion | 13.6% |
Asset Composition Trend (1999–2024)
This chart illustrates how Edwards Lifesciences Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Edwards Lifesciences Corp's current assets represent 48.1% of total assets in 2024, an increase from 24.8% in 1999.
- Cash Position: Cash and equivalents constituted 23.3% of total assets in 2024, up from 0.0% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, a decrease from 68.0% in 1999.
- Asset Diversification: The largest asset category is cash and equivalents at 23.3% of total assets.
Edwards Lifesciences Corp Competitors by Total Assets
Key competitors of Edwards Lifesciences Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Edwards Lifesciences Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Edwards Lifesciences Corp generates 0.42x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Edwards Lifesciences Corp generates $ 31.98 in net profit.
Edwards Lifesciences Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.00 | 3.46 | 3.46 |
| Quick Ratio | 3.29 | 2.89 | 2.56 |
| Cash Ratio | 1.69 | 1.89 | 0.00 |
| Working Capital | $4.77 Billion | $ 4.78 Billion | $ 2.20 Billion |
Edwards Lifesciences Corp - Advanced Valuation Insights
This section examines the relationship between Edwards Lifesciences Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.35 |
| Latest Market Cap to Assets Ratio | 3.41 |
| Asset Growth Rate (YoY) | 39.4% |
| Total Assets | $13.06 Billion |
| Market Capitalization | $44.54 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Edwards Lifesciences Corp's assets at a significant premium ( 3.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Edwards Lifesciences Corp's assets grew by 39.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Edwards Lifesciences Corp (1999–2024)
The table below shows the annual total assets of Edwards Lifesciences Corp from 1999 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $13.06 Billion | +39.43% |
| 2023-12-31 | $9.36 Billion | +12.91% |
| 2022-12-31 | $8.29 Billion | -2.47% |
| 2021-12-31 | $8.50 Billion | +17.49% |
| 2020-12-31 | $7.24 Billion | +11.54% |
| 2019-12-31 | $6.49 Billion | +21.87% |
| 2018-12-31 | $5.32 Billion | -6.54% |
| 2017-12-31 | $5.70 Billion | +26.31% |
| 2016-12-31 | $4.51 Billion | +11.10% |
| 2015-12-31 | $4.06 Billion | +15.18% |
| 2014-12-31 | $3.52 Billion | +29.35% |
| 2013-12-31 | $2.72 Billion | +22.65% |
| 2012-12-31 | $2.22 Billion | +12.17% |
| 2011-12-31 | $1.98 Billion | +12.07% |
| 2010-12-31 | $1.77 Billion | +9.39% |
| 2009-12-31 | $1.62 Billion | +15.38% |
| 2008-12-31 | $1.40 Billion | +4.10% |
| 2007-12-31 | $1.35 Billion | +7.88% |
| 2006-12-31 | $1.25 Billion | +1.44% |
| 2005-12-31 | $1.23 Billion | +10.46% |
| 2004-12-31 | $1.11 Billion | +1.03% |
| 2003-12-31 | $1.10 Billion | +9.24% |
| 2002-12-31 | $1.01 Billion | +3.62% |
| 2001-12-31 | $973.00 Million | -10.57% |
| 2000-12-31 | $1.09 Billion | -24.29% |
| 1999-12-31 | $1.44 Billion | -- |